Fomivirsen

Brand names: Vitravene™

Last updated: 7/1/2002

Important Disclaimer: The drug information provided here is for educational purposes only. It is intended to supplement, not substitute for, the diagnosis, treatment and advice of a medical professional. This drug information does not cover all possible uses, precautions, side effects and interactions. It should not be construed to indicate that this or any drug is safe for you. Consult your medical professional for guidance before using any prescription or over the counter drugs.

Fomivirsen
Systematic (IUPAC) name
?
Identifiers
CAS number	160369-77-7
ATC code	S01AD08
PubChem	?
Chemical data
Formula	C204H263N63O114P20S20
Mol. mass	6682.4 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	B2
Legal status
Routes	Intravitreal injection

Fomivirsen (brand name Vitravene) is an antiviral drug. It is used in the treatment of cytomegalovirus retinitis (CMV) in immunocompromised patients, including those with AIDS.

It is synthetic 21 member oligonucleotide with phosphorothioate linkages (which are resistant to degradation by nucleases) and has the sequence:

• 5'-GCG TTT GCT CTT CTT CTT GCG-3'

Contents 1 Mechanism 2 Administration 3 See also 4 References 5 Further reading 6 External links

Mechanism

It is an oligonucleotide^[1] that blocks translation of viral mRNA by binding to a coding segment of a key CMV gene. It was the first antisense antiviral approved by the FDA.^[2]

Administration

It is available as an intraocular injection in a concentration of 6.6 mg/mL.^[3]

See also

• retinitis

References

1. ^ Mulamba GB, Hu A, Azad RF, Anderson KP, Coen DM (April 1998). "Human cytomegalovirus mutant with sequence-dependent resistance to the phosphorothioate oligonucleotide fomivirsen (ISIS 2922)". Antimicrob. Agents Chemother. 42 (4): 971–3. PMID 9559825. PMC 105584. http://aac.asm.org/cgi/pmidlookup?view=long&pmid=9559825. 
2. ^ Roush W (May 1997). "Antisense aims for a renaissance". Science 276 (5316): 1192–3. doi:10.1126/science.276.5316.1192. PMID 9182327. 
3. ^ Katzung, Bertram G. (2006). Basic and Clinical Pharmacology (10th ed.). New York: McGraw-Hill Medical Publishing Division. pp. 817. ISBN 0-07-145153-6. 

Further reading

• "Fomivirsen.". Drugs Today (Barc) 37 (4): 245–255. 2001. PMID 12768225. 
• Geary R, Henry S, Grillone L (2002). "Fomivirsen: clinical pharmacology and potential drug interactions.". Clin Pharmacokinet 41 (4): 255–60. PMID 11978144. 
• "Randomized dose-comparison studies of intravitreous fomivirsen for treatment of cytomegalovirus retinitis that has reactivated or is persistently active despite other therapies in patients with AIDS.". Am J Ophthalmol 133 (4): 475–83. 2002. doi:10.1016/S0002-9394(02)01326-0. PMID 11931781. 
• Roehr B (1998). "Fomivirsen approved for CMV retinitis.". J Int Assoc Physicians AIDS Care 4 (10): 14–6. PMID 11365956. 

External links

• MedlinePlus DrugInfo uspdi-203675
• DDB 31313
• "Vitravene (Fomivirsen) Drug Information: Uses, Side Effects, Drug Interactions and Warning". RxList. 2004-12-08. http://www.rxlist.com/cgi/generic2/fomivirsen.htm. Retrieved 2009-05-20. 

This antimicrobial-related article is a stub. You can help Wikipedia by expanding it. v • d • e

v • d • e DNA virus Antivirals (primarily J05, also S01AD and D06BB) Baltimore I Herpesvirus DNA synthesis inhibitor TK activated Purine analogue guanine (Aciclovir#/Valaciclovir, Ganciclovir/Valganciclovir, Penciclovir/Famciclovir) adenine (Vidarabine, Cytarabine) Pyrimidine analogue uridine (Idoxuridine, Trifluridine, Edoxudine) thymine (Brivudine) Not TK activated Foscarnet Other Docosanol · early protein (Fomivirsen) · Tromantadine HPV/MC Imiquimod/Resiquimod · Podophyllotoxin Vaccinia assembly: Rifampicin Poxviridae Methisazone Hepatitis B (VII) Nucleoside analogues/NARTIs: Entecavir · Lamivudine · Telbivudine · Clevudine Nucleotide analogues/NtRTIs: Adefovir · Tenofovir Multiple/general Nucleic acid inhibitors Cidofovir Interferon Interferon alfa-2b · Peginterferon alfa-2a Multiple/unknown Ribavirin#/Taribavirin† ErbB2/PI3K Pathway NOV-205§ · NOV-002† #WHO-EM. ‡Withdrawn from market. CLINICAL TRIALS: †Phase III. §Never to phase III

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)